Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Alvotech (ALVO) Investigation

NEW YORK, NY / ACCESSWIRE / April 14, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alvotech ("Alvotech" or the "Company") (NASDAQ:ALVO). Investors who purchased Alvotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/alvo.

The investigation concerns whether Alvotech has violated federal securities laws.

On April 13, 2023, Alvotech issued a press release "announc[ing]…that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira® (adalimumab). The CRL noted that certain deficiencies, which were conveyed following the FDA's reinspection of the company's Reykjavik facility that concluded on March 17, 2023, must be satisfactorily resolved before the application can be approved." On this news, Alvotech's stock price fell sharply during intraday trading on April 14, 2023.

If you are aware of any facts relating to this investigation or purchased Alvotech shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/alvo. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.

Attorney Advertising.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ACCESSWIRE

News network reaching more than 1,500 media outlets in 98 countries. The newest, fastest-growing and most disruptive newswire available today.